Last reviewed · How we verify
Oral anti-diabetic drugs
Oral anti-diabetic drugs is a Oral anti-diabetic agents (multiple classes) Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Type 2 diabetes mellitus.
Oral anti-diabetic drugs work by improving blood glucose control through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption reduction.
Oral anti-diabetic drugs work by improving blood glucose control through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption reduction. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Oral anti-diabetic drugs |
|---|---|
| Sponsor | Sanofi |
| Drug class | Oral anti-diabetic agents (multiple classes) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This is a broad drug class rather than a single entity, encompassing multiple mechanistic approaches such as sulfonylureas (stimulating pancreatic insulin release), metformin (reducing hepatic glucose production and improving insulin sensitivity), DPP-4 inhibitors (prolonging GLP-1 action), SGLT2 inhibitors (promoting urinary glucose excretion), and thiazolidinediones (enhancing peripheral insulin sensitivity). The specific mechanism depends on which agent within this class is being developed.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbances
- Weight gain
- Lactic acidosis (metformin-associated)
Key clinical trials
- The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy (PHASE2, PHASE3)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Anti-Diabetic Medications to Fight PD and LBD (PHASE4)
- Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy
- A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec (PHASE3)
- A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3) (PHASE3)
- A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) (PHASE3)
- Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral anti-diabetic drugs CI brief — competitive landscape report
- Oral anti-diabetic drugs updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Oral anti-diabetic drugs
What is Oral anti-diabetic drugs?
How does Oral anti-diabetic drugs work?
What is Oral anti-diabetic drugs used for?
Who makes Oral anti-diabetic drugs?
What drug class is Oral anti-diabetic drugs in?
What development phase is Oral anti-diabetic drugs in?
What are the side effects of Oral anti-diabetic drugs?
Related
- Drug class: All Oral anti-diabetic agents (multiple classes) drugs
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: Oral anti-diabetic drugs vs similar drugs
- Pricing: Oral anti-diabetic drugs cost, discount & access